Multiple Sclerosis Impacts 1M People In US - Immunic Reveals 'Positive' Data From Nerve Disorder Candidate
Portfolio Pulse from Vandana Singh
Immunic Inc (NASDAQ:IMUX) has announced positive interim data from its phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS). The data showed consistent serum NfL responses and promising GFAP data. The company believes these results corroborate separate findings from its phase 2 EMPhASIS trial. Following the announcement, IMUX shares are up 13.20% at $1.80 during the premarket session.
October 10, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive interim data from Immunic's phase 2 trial of IMU-838 in PMS patients has led to a 13.20% increase in the company's share price.
The positive interim data from Immunic's phase 2 trial of IMU-838 in PMS patients is a significant development for the company. This has led to increased investor confidence, reflected in the 13.20% increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100